These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 16369935

  • 1. Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses.
    Berry V, Magill A, Yost M, Janosky J, Sindhi R.
    Cytometry A; 2006 Feb; 69(2):95-103. PubMed ID: 16369935
    [Abstract] [Full Text] [Related]

  • 2. Modeling individual variation in biomarker response to combination immunosuppression with stimulated lymphocyte responses-potential clinical implications.
    Sindhi R, Allaert J, Gladding D, Haaland P, Koppelman B, Dunne J, Sehgal S.
    J Immunol Methods; 2003 Jan 15; 272(1-2):257-72. PubMed ID: 12505729
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients.
    Böhler T, Canivet C, Galvani S, Therville N, Salvayre R, Negre-Salvayre A, Durand D, Thomsen M, Rostaing L, Kamar N.
    Int Immunopharmacol; 2008 May 15; 8(5):769-73. PubMed ID: 18387521
    [Abstract] [Full Text] [Related]

  • 4. Assessment of immunosuppressive drug interactions: inhibition of lymphocyte function in peripheral human blood.
    Barten MJ, Dhein S, Chang H, Bittner HB, Tarnok A, Rahmel A, Mohr FW, Gummert JF.
    J Immunol Methods; 2003 Dec 15; 283(1-2):99-114. PubMed ID: 14659903
    [Abstract] [Full Text] [Related]

  • 5. Cytokines and cell surface receptors as target end points of immunosuppression with cyclosporine A.
    Sindhi R, Allaert J, Gladding D, Koppelman B, Dunne JF.
    J Interferon Cytokine Res; 2001 Jul 15; 21(7):507-14. PubMed ID: 11506745
    [Abstract] [Full Text] [Related]

  • 6. Antiproliferative profile of sirolimus and mycophenolate mofetil: impact of the SI/MPL ratio.
    Voisard R, Geçgüner L, Baur R, Herter T, Hombach V.
    Int J Cardiol; 2005 Jul 20; 102(3):435-42. PubMed ID: 16004888
    [Abstract] [Full Text] [Related]

  • 7. Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients.
    Weigel G, Griesmacher A, Karimi A, Zuckermann AO, Grimm M, Mueller MM.
    J Heart Lung Transplant; 2002 Oct 20; 21(10):1074-9. PubMed ID: 12398872
    [Abstract] [Full Text] [Related]

  • 8. The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo.
    Libetta C, Sepe V, Zucchi M, Portalupi V, Meloni F, Rampino T, Dal Canton A.
    Kidney Int; 2007 Jul 20; 72(1):114-20. PubMed ID: 17410097
    [Abstract] [Full Text] [Related]

  • 9. Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B Cells.
    Traitanon O, Mathew JM, La Monica G, Xu L, Mas V, Gallon L.
    PLoS One; 2015 Jul 20; 10(6):e0129658. PubMed ID: 26087255
    [Abstract] [Full Text] [Related]

  • 10. CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis.
    Kilmartin DJ, Fletcher ZJ, Almeida JA, Liversidge J, Forrester JV, Dick AD.
    Invest Ophthalmol Vis Sci; 2001 May 20; 42(6):1285-92. PubMed ID: 11328741
    [Abstract] [Full Text] [Related]

  • 11. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood.
    Barten MJ, Streit F, Boeger M, Dhein S, Tarnok A, Shipkova M, Armstrong VW, Mohr FW, Oellerich M, Gummert JF.
    Transplantation; 2004 Apr 27; 77(8):1154-62. PubMed ID: 15114077
    [Abstract] [Full Text] [Related]

  • 12. Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection.
    Klupp J, van Gelder T, Dambrin C, Regieli JJ, Boeke K, Billingham ME, Morris RE.
    J Heart Lung Transplant; 2004 Mar 27; 23(3):334-51. PubMed ID: 15019644
    [Abstract] [Full Text] [Related]

  • 13. [Proliferation effects of sirolimus, cyclosporine A and mycophenolate mofetil on human transitional cell carcinoma cells].
    Lin J, Wang YH, Zhang YH, Tian Y.
    Zhonghua Yi Xue Za Zhi; 2012 Feb 14; 92(6):388-91. PubMed ID: 22490898
    [Abstract] [Full Text] [Related]

  • 14. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood.
    Dieterlen MT, Bittner HB, Klein S, von Salisch S, Mittag A, Tárnok A, Dhein S, Mohr FW, Barten MJ.
    Cytometry B Clin Cytom; 2012 May 14; 82(3):151-7. PubMed ID: 22213594
    [Abstract] [Full Text] [Related]

  • 15. Conversion to combined therapy with sirolimus and mycophenolate mofetil improved renal function in stable renal transplant recipients.
    Tsai MK, Lee CY, Hu RH, Lee PH.
    J Formos Med Assoc; 2007 May 14; 106(5):372-9. PubMed ID: 17561472
    [Abstract] [Full Text] [Related]

  • 16. Novel assays of multiple lymphocyte functions in whole blood measure: new mechanisms of action of mycophenolate mofetil in vivo.
    Barten MJ, van Gelder T, Gummert JF, Shorthouse R, Morris RE.
    Transpl Immunol; 2002 Jun 14; 10(1):1-14. PubMed ID: 12182459
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.